User: Guest

SHORT BOWEL SYNDROME (SBS)

Global Market Trajectory & Analytics

MCP14715

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

382

Interactions with Platform & by Email *

INTERACTIONS

76

Unique # Participated *

PARTICIPANTS

13

Responses Validated *

VALIDATIONS

6

* Login to view program details and full enterprise executive list.


  •  DATE

    JULY 2020

  •  TABLES

    60

  •  PAGES

    132

  •  EDITION

    7

  •  PRICE

    USD $4950


COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for Short Bowel Syndrome (SBS) estimated at US$665.4 Million in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 27.6% over the analysis period 2020-2027.GLP-2, one of the segments analyzed in the report, is projected to grow at a 29% CAGR to reach US$3 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Growth Hormone segment is readjusted to a revised 26.4% CAGR for the next 7-year period. This segment currently accounts for a 4.8% share of the global Short Bowel Syndrome (SBS) market.
The Short Bowel Syndrome (SBS) market in the U.S. is estimated at US$199.7 Million in the year 2020. The country currently accounts for a 30.01% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$627.8 Million in the year 2027 trailing a CAGR of 26.8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 25% and 23.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 19.2% CAGR while Rest of European market (as defined in the study) will reach US$627.8 Million by the year 2027.
In the global Glutamine segment, USA, Canada, Japan, China and Europe will drive the 23.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$19.7 Million in the year 2020 will reach a projected size of US$86.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433 Million by the year 2027.We bring years of research experience to this 7th edition of our report. The 132-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, Ardelyx, Inc.; Emmaus Life Sciences, Inc.; Merck KgaA; Naia Pharmaceuticals Inc.; Nutrien Ltd.; OxThera AB; Shire PLC; Zealand Pharma A/S
» Drug Class (GLP-2, Growth Hormone, Glutamine, Other Drug Classes)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com